Biodistribution of phenylboric acid derivative entrapped lipiodol and 4-borono-2-18F-fluoro-l-phenylalanine-fructose in GP7TB liver tumor bearing rats for BNCT

A new phenylboric acid derivative entrapped lipiodol (PBAD-lipiodol) was developed as a boron carrier for the boron neutron capture therapy (BNCT) of hepatoma in Taiwan. The biodistribution of both PBAD-lipiodol and BPA-fructose was assayed in GP7TB hepatoma-bearing rat model. The highest uptake of PBAD-lipiodol was found at 2 h post injection. The application of BNCT for the hepatoma treatment in tumor-bearing rats is suggested to be 2–4 h post PBAD-lipiodol injection.